Provectus announced that updated data from the Company's initial expansion cohort of patients with uveal melanoma metastatic to the liver (mUM) in its cancers-of-the-liver Phase 1 trial of investigational immunocatalyst PV-10 (NCT00986661) were part of two oral presentations at the 20thCongress of the International Society of Ocular Oncology (ISOO), held June 17-21, 2022 in Leiden, The Netherlands. The first presentation, given by Krysta McVay, Research Nurse, Department of Melanoma Medical Oncology, Division of Cancer Medicine at MD Anderson Cancer Center (MDACC), was entitled “A phase 1 study of percutaneous autolytic rose bengal disodium for metastatic uveal melanoma patients with hepatic metastases. This ongoing single-center mUM study at MDACC has been led since inception by Dr. Patel.

Up to three hepatic mUM tumors can be injected per PV-10 treatment cycle. Response assessments are performed at Day 28, and then every three months. Patients with additional, injectable, visceral hepatic mUM disease may receive additional cycles of PV-10 after Day 28.

Eligible patients may also receive standard of care immune checkpoint blockade during and after PV-10 treatment.